EGFR and non-small cell lung carcinoma: Furthermore, absence of a control arm, testing predominantly white population and the drug being tested on previously treated EGFR- non-squamous NSCLC has brought selection bias, some of which are said to be addressed in the Phase III LUMINOSITY trial (40).